Last Price$137.11.5%
Market Cap$237.5B
LTM Net Debt to Free Cash Flow
1.1x
5Y avg
1.6x
Medical - Devices industry
median
0.4x
Stock quality & Intrinsic value
7/10
0.3% undervalued
Abbott Laboratories Net Debt to Free Cash Flow
Annual
Quarterly
LTM
Industry median
Company stand-alone
Crunching data... Almost there!
| Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Debt to Free Cash Flow | 0.9x | 2.8x | 2.7x | 1.1x | 1.1x | 1.7x | 1.0x | 0.7x | (0.7x) | 1.3x | 1.5x | 1.6x | 4.1x | 3.2x | 3.3x | 2.2x | 1.0x | 1.0x | 1.7x | 1.1x |
Overvalued or undervalued?
Check the intrinsic value for ABT
and see if it's the right time to invest.
Abbott Laboratories (ABT) Net Debt to Free Cash Flow comparison analysis
General
LTM Net Debt to Free Cash Flow
OTHER METRICS
Company name
Revenue growth
EPS growth
Net Income margin
Abbott LaboratoriesABT
1.1x
4.6%
134.5%
31.9%
Median Peer Set
1.1x
3.7%
21.3%
11.6%
Koninklijke Philips N.V.PHG
19.1x
(0.8%)
83.7%
(3.9%)
Zimmer Biomet Holdings, Inc.ZBH
5.0x
3.8%
(9.4%)
11.8%
Medtronic plcMDT
4.6x
3.6%
(2.1%)
11.4%
Boston Scientific CorporationBSX
4.4x
17.6%
16.7%
11.1%
Stryker CorporationSYK
2.2x
10.2%
(5.8%)
13.2%
STERIS plcSTE
(0.0x)
3.6%
257.9%
7.4%
DexCom, Inc.DXCM
(0.1x)
11.3%
(1.4%)
14.3%
Align Technology, Inc.ALGN
(1.5x)
3.4%
26.0%
11.5%
Insulet CorporationPODD
(2.9x)
22.1%
101.7%
20.2%
Edwards Lifesciences CorporationEW
(11.3x)
(9.4%)
202.2%
76.7%
ABT key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 22,337.8 13.5% | 22,476.3 0.6% | 25,914.2 15.3% | 29,527.6 13.9% | 30,765.0 4.2% | 35,167.0 14.3% | 38,851.0 10.5% | 39,874.0 2.6% | 21,848.0 (45.2%) | 20,247.0 (7.3%) | 20,405.0 0.8% | 20,853.0 2.2% | 27,390.0 31.3% | 30,578.0 11.6% | 31,904.0 4.3% | 34,608.0 8.5% | 43,075.0 24.5% | 43,653.0 1.3% | 40,109.0 (8.1%) | 41,950.0 4.6% |
| Cost of Goods Sold (COGS) | 10,641.1 | 9,815.1 | 11,422.0 | 12,612.0 | 13,209.0 | 14,665.0 | 15,541.0 | 15,120.0 | 10,040.0 | 9,218.0 | 8,747.0 | 9,024.0 | 12,337.0 | 12,706.0 | 13,231.0 | 15,003.0 | 18,537.0 | 19,142.0 | 17,975.0 | 18,706.0 |
% margin | 11,696.7 52.4% | 12,661.2 56.3% | 14,492.2 55.9% | 16,915.5 57.3% | 17,556.0 57.1% | 20,502.0 58.3% | 23,310.0 60.0% | 24,754.0 62.1% | 11,808.0 54.0% | 11,029.0 54.5% | 11,658.0 57.1% | 11,829.0 56.7% | 15,053.0 55.0% | 17,872.0 58.4% | 18,673.0 58.5% | 19,605.0 56.6% | 24,538.0 57.0% | 24,511.0 56.1% | 22,134.0 55.2% | 23,244.0 55.4% |
| Operating Expenses | 7,317.3 | 8,605.0 | 9,913.6 | 11,124.4 | 11,150.0 | 14,101.0 | 17,558.0 | 16,381.0 | 9,179.0 | 8,430.0 | 8,791.0 | 8,644.0 | 13,327.0 | 14,222.0 | 14,141.0 | 14,248.0 | 16,113.0 | 16,149.0 | 15,656.0 | 16,419.0 |
| Research & Development Expenses (R&D) | 1,821.2 | 2,255.3 | 2,505.6 | 2,688.8 | 2,744.0 | 3,725.0 | 4,802.0 | 4,322.0 | 1,452.0 | 1,345.0 | 1,405.0 | 1,422.0 | 2,235.0 | 2,300.0 | 2,440.0 | 2,420.0 | 2,742.0 | 2,888.0 | 2,741.0 | 2,844.0 |
| Selling, General & Administrative Expenses (SG&A) | 5,496.1 | 6,349.7 | 7,408.0 | 8,435.6 | 8,406.0 | 10,376.0 | 12,756.0 | 12,059.0 | 6,936.0 | 6,530.0 | 6,785.0 | 6,672.0 | 9,117.0 | 9,744.0 | 9,765.0 | 9,696.0 | 11,324.0 | 11,248.0 | 10,949.0 | 11,697.0 |
% margin | 4,362.3 19.5% | 2,042.2 9.1% | 4,578.5 17.7% | 5,693.8 19.3% | 6,236.0 20.3% | 6,088.0 17.3% | 5,752.0 14.8% | 8,085.0 20.3% | 2,629.0 12.0% | 2,599.0 12.8% | 2,867.0 14.1% | 3,185.0 15.3% | 1,726.0 6.3% | 3,650.0 11.9% | 4,532.0 14.2% | 5,357.0 15.5% | 8,425.0 19.6% | 8,362.0 19.2% | 6,478.0 16.2% | 6,825.0 16.3% |
| Interest Income | 0.0 | 0.0 | 0.0 | 201.2 | 137.8 | 105.5 | 85.2 | 79.2 | 67.0 | 77.0 | 105.0 | 99.0 | 124.0 | 105.0 | 94.0 | 46.0 | 43.0 | 183.0 | 385.0 | 344.0 |
| Interest Expense | 153.7 | 292.3 | 593.1 | 528.5 | 382.0 | 553.1 | 530.1 | 513.0 | 90.0 | 73.0 | 58.0 | 332.0 | 780.0 | 721.0 | 576.0 | 500.0 | 490.0 | 375.0 | 637.0 | 559.0 |
| Pre-tax Income | 4,619.9 | 2,276.4 | 4,469.6 | 5,856.3 | 7,194.0 | 5,713.0 | 5,199.0 | 6,263.0 | 2,521.0 | 2,518.0 | 3,183.0 | 1,413.0 | 2,231.0 | 2,873.0 | 4,077.0 | 4,968.0 | 8,211.0 | 8,306.0 | 6,664.0 | 7,013.0 |
% effective tax rate | 1,247.9 27.0% | 559.6 24.6% | 863.3 19.3% | 1,122.1 19.2% | 1,448.0 20.1% | 1,087.0 19.0% | 470.0 9.0% | 300.0 4.8% | 138.0 5.5% | 797.0 31.7% | 577.0 18.1% | 350.0 24.8% | 1,878.0 84.2% | 539.0 18.8% | 390.0 9.6% | 497.0 10.0% | 1,140.0 13.9% | 1,373.0 16.5% | 941.0 14.1% | (6,389.0) (91.1%) |
% margin | 3,372.1 15.1% | 1,716.8 7.6% | 3,606.3 13.9% | 4,880.7 16.5% | 5,745.8 18.7% | 4,626.2 13.2% | 4,728.0 12.2% | 5,963.0 15.0% | 2,576.0 11.8% | 2,284.0 11.3% | 4,423.0 21.7% | 1,400.0 6.7% | 477.0 1.7% | 2,368.0 7.7% | 3,687.0 11.6% | 4,495.0 13.0% | 7,071.0 16.4% | 6,933.0 15.9% | 5,723.0 14.3% | 13,402.0 31.9% |
| EPS | 2.17 | 1.12 | 2.34 | 3.16 | 3.72 | 2.99 | 3.01 | 3.78 | 1.66 | 1.51 | 3.00 | 0.95 | 0.27 | 1.35 | 2.07 | 2.52 | 3.97 | 3.94 | 3.30 | 7.74 |
| Diluted EPS | 2.16 | 1.12 | 2.31 | 3.13 | 3.70 | 2.97 | 3.01 | 3.75 | 1.64 | 1.50 | 2.94 | 0.94 | 0.27 | 1.34 | 2.06 | 2.50 | 3.94 | 3.91 | 3.27 | 7.67 |
% margin | 6,220.2 27.8% | 4,251.3 18.9% | 6,433.4 24.8% | 8,223.6 27.9% | 9,493.9 30.9% | 9,138.3 26.0% | 9,260.7 23.8% | 3,496.0 8.8% | 3,452.0 15.8% | 4,216.0 20.8% | 4,833.0 23.7% | 3,070.0 14.7% | 6,132.0 22.4% | 7,116.0 23.3% | 7,771.0 24.4% | 8,789.0 25.4% | 12,742.0 29.6% | 12,380.0 28.4% | 10,605.0 26.4% | 10,834.0 25.8% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is Abbott Laboratories's Net Debt to Free Cash Flow?
As of today, Microsoft Corp's last 12-month Net Debt to Free Cash Flow is 1.1x, based on the financial report for Dec 31, 2024 (Q4’2024). The average annual Net Debt to Free Cash Flow for Abbott Laboratories have been 1.2x over the past three years, and 1.7x over the past five years.
2) Is Abbott Laboratories's Net Debt to Free Cash Flow Good?
As of today, Abbott Laboratories's Net Debt to Free Cash Flow is 1.1x, which is higher than industry median of 0.4x. It indicates that Abbott Laboratories's Net Debt to Free Cash Flow is Bad.